title: Efficacy of flutrimazole 1% powder in the treatment of tinea pedis.
abstract: The aim of the study was to compare the efficacy and tolerability of flutrimazole 1% powder vs. bifonazole 1% powder in treating tinea pedis. A multicentre, double blind, randomized, parallel and comparative study was conducted. Two hundred and twenty-two patients with clinically and mycologically confirmed tinea pedis were randomized to flutrimazole (n = 136) or bifonazole (n = 138) 1% powder applied twice daily for 4 weeks. The corresponding clinical cure rates were assessed at 2 and 4 weeks of treatment, and the global (clinical and mycological) cure rates were determined at the fourth week. Clinical cure rates were 83.5 and 82.4% for flutrimazole and bifonazole, respectively (95% CI: -0.0806 to 0.1009). Global cure rates were observed in 65.3 and 70.1% of patients treated with flutrimazole and bifonazole, respectively (95% CI: -0.0828 to 0.1779). Three non serious adverse events at the application site--itching (one patient per group) and dishydrotic eczema (one patient treated with flutrimazole)--were recorded during the study. These results support that flutrimazol 1% powder applied twice daily for a duration of 4 weeks is highly effective in the treatment of tinea pedis, showing a similar therapeutic profile with that of bifonazole 1% powder.
authors.affiliation: Service of Dermatology, Hospital Naval del Mediterráneo, Cartagena, Murcia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Pereda
authors.forename: X
authors.initials: X
authors.lastname: Noguera
authors.forename: E
authors.initials: E
authors.lastname: Boncompte
authors.forename: M
authors.initials: M
authors.lastname: Algueró
authors.forename: I
authors.initials: I
authors.lastname: Izquierdo
mesh_terms: D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003022:Clotrimazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D011208:Powders; D014008:Tinea Pedis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome; D014249:Trichophyton / Q000187:drug effects
chemical_list: D000935:Antifungal Agents; D007093:Imidazoles; D011208:Powders; C076986:flutrimazole; D003022:Clotrimazole; C036596:bifonazole